SCHEMBL238676

SCHEMBL238676

CCOC(=O)c1c(C)nc2cc(C(C)C)nn2c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.44
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
LMNA P02545 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 3/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PDE4D Q08499 1/20 0.41
PKM P14618 1/20 0.40
TSHR P16473 2/20 0.40
NPC1 O15118 2/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239438 0.87 MAPK1 (0.48) MAPK1POLBSMN1; SMN2LMNAKMT2A
SCHEMBL238224 0.80 PLAT (0.43) MAPK1POLBSMN1; SMN2LMNAKMT2A
SCHEMBL238840 0.78 NPC1 (0.64) POLBSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL239388 0.75 PDE4A (0.49) MAPK1SMN1; SMN2LMNAKMT2AMEN1
SCHEMBL20723221 0.74 KDM4E (0.43) POLBSMN1; SMN2KMT2AHPGDKDM4E
SCHEMBL2755156 0.73 HPGD (0.48) KMT2AMEN1HPGDKDM4ERAB9A
SCHEMBL239374 0.73 NPC1 (0.37) SMN1; SMN2LMNAKMT2AMEN1HPGD
SCHEMBL5066763 0.72 POLB (0.45) MAPK1POLBSMN1; SMN2LMNAKMT2A
SCHEMBL5826452 0.70 ALDH1A1 (0.46) MAPK1SMN1; SMN2LMNAKMT2AMEN1
SCHEMBL16058847 0.70 MAPK1 (0.52) MAPK1POLBSMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
EP-2406250-A1 INHIBITORS OF AKT ACTIVITY Merck Sharp & Dohme Corp. (US) 2012-01-18 EP disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 MAPK1 171/4885POLB 1307/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.